By Mill Chart
Last update: May 15, 2025
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) stands out as an affordable growth stock based on its strong fundamentals. The company, which focuses on rare disease treatments, combines solid growth with reasonable valuation, making it an interesting option for investors seeking growth at a sensible price.
CPRX has demonstrated impressive growth metrics:
These figures place CPRX well above industry averages, earning it a Growth Rating of 9/10.
Despite its strong growth, CPRX remains reasonably priced:
With a Valuation Rating of 7/10, CPRX offers an attractive entry point.
CPRX excels in profitability and financial stability:
CPRX presents a compelling mix of growth, value, and financial strength. Investors looking for affordable growth opportunities in the biotech sector may find this stock worth further research.
For more details, review the full fundamental analysis of CPRX.
Our Affordable Growth screener lists more stocks with similar characteristics and is updated daily.
This is not investing advice. Always conduct your own research before making investment decisions.
22.48
-0.33 (-1.45%)
Find more stocks in the Stock Screener
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and an attractive valuation, making it a standout in biotech.
CATALYST PHARMACEUTICALS (CPRX) meets CANSLIM criteria with strong earnings growth, high relative strength, and solid fundamentals. A technical uptrend and reasonable valuation add to its appeal.
CATALYST PHARMACEUTICALS INC (CPRX) meets key growth criteria from Louis Navellier’s strategy, with strong earnings, revenue growth, and solid financial health. A detailed analysis highlights its potential for investors.